Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to accelerate the next generation of precision medicines for immune-mediated diseases and fibrotic diseases by leveraging its proprietary Mirador360TM development engine to rapidly advance multiple programs.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 21, 2024